Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Introduction to special issue: Therapeutic and abuse-related effects of cannabis and cannabinoids.

Acheson A, Fantegrossi WE.

Exp Clin Psychopharmacol. 2019 Aug;27(4):299-300. doi: 10.1037/pha0000308.

PMID:
31355665
2.

Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in rats.

Hyatt WS, Berquist MD, Chitre NM, Russell LN, Rice KC, Murnane KS, Fantegrossi WE.

Behav Pharmacol. 2019 Oct;30(7):555-565. doi: 10.1097/FBP.0000000000000492.

PMID:
31211703
3.

In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome.

Griffin BA, Caperton CO, Russell LN, Cabanlong CV, Wilson CD, Urquhart KR, Martins BS, Zita MD, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH, Brents LK.

J Pharmacol Exp Ther. 2019 Jul;370(1):9-17. doi: 10.1124/jpet.118.254219. Epub 2019 Apr 26.

PMID:
31028107
4.

Reduced Tolerance and Asymmetrical Crosstolerance to Effects of the Indole Quinuclidinone Analog PNR-4-20, a G Protein-Biased Cannabinoid 1 Receptor Agonist in Mice: Comparisons with Δ9-Tetrahydrocannabinol and JWH-018.

Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE.

J Pharmacol Exp Ther. 2019 May;369(2):259-269. doi: 10.1124/jpet.118.252965. Epub 2019 Mar 4.

PMID:
30833484
5.

Enzymatic analysis of glucuronidation of synthetic cannabinoid 1-naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22).

Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R.

Xenobiotica. 2019 Dec;49(12):1388-1395. doi: 10.1080/00498254.2019.1580403. Epub 2019 Mar 20.

PMID:
30739533
6.

Convulsant Effects of Abused Synthetic Cannabinoids JWH-018 and 5F-AB-PINACA Are Mediated by Agonist Actions at CB1 Receptors in Mice.

Wilson CD, Tai S, Ewing L, Crane J, Lockhart T, Fujiwara R, Radominska-Pandya A, Fantegrossi WE.

J Pharmacol Exp Ther. 2019 Feb;368(2):146-156. doi: 10.1124/jpet.118.251157. Epub 2018 Nov 12.

PMID:
30420360
7.

Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ9-THC.

Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL.

Front Pharmacol. 2018 Sep 26;9:1084. doi: 10.3389/fphar.2018.01084. eCollection 2018.

8.

Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice.

Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE.

Drug Alcohol Depend. 2018 Nov 1;192:285-293. doi: 10.1016/j.drugalcdep.2018.08.011. Epub 2018 Sep 25.

PMID:
30300803
9.

Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6-O-sulfate in rats: Drug discrimination and physical dependence.

Yadlapalli JSK, Bommagani SB, Mahelona RD, Wan A, Gannon BM, Penthala NR, Dobretsov M, Crooks PA, Fantegrossi WE.

Pharmacol Res Perspect. 2018 Jun 19;6(4):e00403. doi: 10.1002/prp2.403. eCollection 2018 Jul.

10.

Cocaine-Responsive miRNA and Blood Pressure Elevation.

Mu S, Fantegrossi WE, Rusch NJ.

Hypertension. 2018 Apr;71(4):561-562. doi: 10.1161/HYPERTENSIONAHA.118.10278. Epub 2018 Feb 26. No abstract available.

PMID:
29483229
11.

Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems.

Fantegrossi WE, Wilson CD, Berquist MD.

Drug Metab Rev. 2018 Feb;50(1):65-73. doi: 10.1080/03602532.2018.1428343. Epub 2018 Jan 31. Review.

12.

Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice.

Gannon BM, Williamson A, Rice KC, Fantegrossi WE.

Neuropharmacology. 2018 May 15;134(Pt A):13-21. doi: 10.1016/j.neuropharm.2017.09.004. Epub 2017 Sep 5.

13.

Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice.

Gannon BM, Russell LN, Modi MS, Rice KC, Fantegrossi WE.

Drug Alcohol Depend. 2017 Oct 1;179:408-415. doi: 10.1016/j.drugalcdep.2017.06.031. Epub 2017 Aug 4.

14.

Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development.

Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL.

Pharmacol Res. 2017 Nov;125(Pt B):161-177. doi: 10.1016/j.phrs.2017.08.008. Epub 2017 Aug 23.

15.

Phencyclidine-like in vivo effects of methoxetamine in mice and rats.

Berquist MD, Hyatt WS, Bauer-Erickson J, Gannon BM, Norwood AP, Fantegrossi WE.

Neuropharmacology. 2018 May 15;134(Pt A):158-166. doi: 10.1016/j.neuropharm.2017.08.028. Epub 2017 Aug 19.

16.

Monoaminergic toxicity induced by cathinone phthalimide: An in vitro study.

Lantz SM, Rosas-Hernandez H, Cuevas E, Robinson B, Rice KC, Fantegrossi WE, Imam SZ, Paule MG, Ali SF.

Neurosci Lett. 2017 Aug 10;655:76-81. doi: 10.1016/j.neulet.2017.06.059. Epub 2017 Jul 3.

17.

Discriminative Stimulus Effects of Psychostimulants.

Berquist MD, Fantegrossi WE.

Curr Top Behav Neurosci. 2018;39:29-49. doi: 10.1007/7854_2017_5. Review.

PMID:
28341944
18.

Synthetic Pot: Not Your Grandfather's Marijuana.

Ford BM, Tai S, Fantegrossi WE, Prather PL.

Trends Pharmacol Sci. 2017 Mar;38(3):257-276. doi: 10.1016/j.tips.2016.12.003. Epub 2017 Feb 2. Review.

19.

Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites.

Tai S, Fantegrossi WE.

Curr Top Behav Neurosci. 2017;32:249-262. doi: 10.1007/7854_2016_60. Review.

20.

Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells.

Rosas-Hernandez H, Cuevas E, Lantz SM, Rice KC, Gannon BM, Fantegrossi WE, Gonzalez C, Paule MG, Ali SF.

Neurosci Lett. 2016 Aug 26;629:125-130. doi: 10.1016/j.neulet.2016.06.029. Epub 2016 Jun 16.

21.

In Vitro and In Vivo Characterization of the Alkaloid Nuciferine.

Farrell MS, McCorvy JD, Huang XP, Urban DJ, White KL, Giguere PM, Doak AK, Bernstein AI, Stout KA, Park SM, Rodriguiz RM, Gray BW, Hyatt WS, Norwood AP, Webster KA, Gannon BM, Miller GW, Porter JH, Shoichet BK, Fantegrossi WE, Wetsel WC, Roth BL.

PLoS One. 2016 Mar 10;11(3):e0150602. doi: 10.1371/journal.pone.0150602. eCollection 2016.

22.

Stereoselective Effects of Abused "Bath Salt" Constituent 3,4-Methylenedioxypyrovalerone in Mice: Drug Discrimination, Locomotor Activity, and Thermoregulation.

Gannon BM, Williamson A, Suzuki M, Rice KC, Fantegrossi WE.

J Pharmacol Exp Ther. 2016 Mar;356(3):615-23. doi: 10.1124/jpet.115.229500. Epub 2016 Jan 14.

23.

Cocaine-Like Discriminative Stimulus Effects of Mephedrone and Naphyrone in Mice.

Gannon BM, Fantegrossi WE.

J Drug Alcohol Res. 2016;5. pii: 236009. doi: 10.4303/jdar/236009. Epub 2016 Dec 31.

24.

Psychostimulant Abuse and HIV Infection: cocaine, methamphetamine, and "bath salts" cathinone analogues.

Gannon BM, Reichard EE, Fantegrossi WE.

Curr Addict Rep. 2014 Sep 1;1(3):237-242.

25.
26.

Baths salts, spice, and related designer drugs: the science behind the headlines.

Baumann MH, Solis E Jr, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL.

J Neurosci. 2014 Nov 12;34(46):15150-8. doi: 10.1523/JNEUROSCI.3223-14.2014. Review.

27.

Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice.

Smith DA, Bailey JM, Williams D, Fantegrossi WE.

J Pharmacol Exp Ther. 2014 Dec;351(3):485-91. doi: 10.1124/jpet.114.219337. Epub 2014 Sep 30.

28.

Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice.

Fantegrossi WE, Gray BW, Bailey JM, Smith DA, Hansen M, Kristensen JL.

Psychopharmacology (Berl). 2015 Mar;232(6):1039-47. doi: 10.1007/s00213-014-3739-3. Epub 2014 Sep 17.

29.

Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential.

Tai S, Fantegrossi WE.

Curr Addict Rep. 2014 Jun 1;1(2):129-136.

30.

In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection.

Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE.

Pharmacol Biochem Behav. 2014 Sep;124:40-7. doi: 10.1016/j.pbb.2014.05.010. Epub 2014 May 21.

31.

Predisposing effects of neonatal visceral pain on abuse-related effects of morphine in adult male Sprague Dawley rats.

Norwood AP, Al-Chaer ED, Fantegrossi WE.

Psychopharmacology (Berl). 2014 Nov;231(22):4281-9. doi: 10.1007/s00213-014-3574-6. Epub 2014 Apr 23.

32.

Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice.

Hyatt WS, Fantegrossi WE.

Behav Pharmacol. 2014 Jun;25(3):253-7. doi: 10.1097/FBP.0000000000000034.

33.

Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS.

Patton AL, Seely KA, Pulla S, Rusch NJ, Moran CL, Fantegrossi WE, Knight LD, Marraffa JM, Kennedy PD, James LP, Endres GW, Moran JH.

Anal Chem. 2014 Feb 4;86(3):1760-6. doi: 10.1021/ac4036197. Epub 2014 Jan 15.

PMID:
24354295
34.

Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds.

Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH.

Forensic Sci Int. 2013 Dec 10;233(1-3):416-22. doi: 10.1016/j.forsciint.2013.10.002. Epub 2013 Oct 14.

PMID:
24314548
35.

Not simply synthetic tetrahydrocannabinol.

Fantegrossi WE, McCain KR, Moran JH, Hoffman RS.

J Pediatr. 2013 Dec;163(6):1797-8. doi: 10.1016/j.jpeds.2013.09.017. Epub 2013 Oct 13. No abstract available.

PMID:
24128645
36.

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL.

Life Sci. 2014 Feb 27;97(1):45-54. doi: 10.1016/j.lfs.2013.09.017. Epub 2013 Sep 29. Review.

37.

Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology.

Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH.

Anal Chem. 2013 Oct 1;85(19):9390-9. doi: 10.1021/ac4024704. Epub 2013 Sep 12.

PMID:
23987522
38.

Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.

Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE.

J Pharmacol Exp Ther. 2013 Sep;346(3):350-61. doi: 10.1124/jpet.113.206003. Epub 2013 Jun 25.

39.

Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.

Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE.

J Med Chem. 2013 Jun 13;56(11):4537-50. doi: 10.1021/jm400268b. Epub 2013 May 22.

40.

In vivo effects of abused 'bath salt' constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice: drug discrimination, thermoregulation, and locomotor activity.

Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC.

Neuropsychopharmacology. 2013 Mar;38(4):563-73. doi: 10.1038/npp.2012.233. Epub 2012 Nov 8.

41.

Novel technology for modulating locomotor activity as an operant response in the mouse: implications for neuroscience studies involving "exercise" in rodents.

Fantegrossi WE, Xiao WR, Zimmerman SM.

J Neurosci Methods. 2013 Jan 30;212(2):338-43. doi: 10.1016/j.jneumeth.2012.10.020. Epub 2012 Nov 16.

42.

AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: implications for opioid/cannabinoid interaction studies.

Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL.

Neuropharmacology. 2012 Oct;63(5):905-15. doi: 10.1016/j.neuropharm.2012.06.046. Epub 2012 Jul 4.

43.

Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity.

Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL.

Biochem Pharmacol. 2012 Apr 1;83(7):952-61. doi: 10.1016/j.bcp.2012.01.004. Epub 2012 Jan 18.

44.

Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry.

Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE.

Psychopharmacology (Berl). 2012 Apr;220(3):495-508. doi: 10.1007/s00213-011-2504-0. Epub 2011 Oct 13.

45.

Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.

Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL.

PLoS One. 2011;6(7):e21917. doi: 10.1371/journal.pone.0021917. Epub 2011 Jul 6.

46.

Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine.

Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH.

Anal Chem. 2011 Jun 1;83(11):4228-36. doi: 10.1021/ac2005636. Epub 2011 May 6.

47.

Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine.

Matsumoto RR, Li SM, Katz JL, Fantegrossi WE, Coop A.

Drug Alcohol Depend. 2011 Oct 1;118(1):40-7. doi: 10.1016/j.drugalcdep.2011.02.017. Epub 2011 Mar 21.

48.

Intravenous Drug Self-Administration in Nonhuman Primates.

Howell LL, Fantegrossi WE.

In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press/Taylor & Francis; 2009. Chapter 9.

49.

Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice.

Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, Woods JH.

J Pharmacol Exp Ther. 2010 Dec;335(3):728-34. doi: 10.1124/jpet.110.172247. Epub 2010 Sep 21.

50.

Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys.

Murnane KS, Fantegrossi WE, Godfrey JR, Banks ML, Howell LL.

J Pharmacol Exp Ther. 2010 Aug;334(2):642-50. doi: 10.1124/jpet.110.166595. Epub 2010 May 13.

Supplemental Content

Loading ...
Support Center